Aggressive Natalizumab Treatment For Jc Virus-Negative Relapsing-Remitting Multiple Sclerosis? Cost-Effectiveness Of First-Line Versus Second-Line Natalizumab Treatment
2018 ◽
Vol 41
(6)
◽
pp. 199-201
◽
2020 ◽
Vol 23
◽
pp. 13-18
◽
2019 ◽
Vol 17
(6)
◽
pp. 857-873
◽